WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug combo targets tough blood cancers
Disease control CompletedThis early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Stem cell transplant shows promise against rare blood cancer
Disease control CompletedThis study tested whether a stem cell transplant (using the patient's own cells) works better than standard chemotherapy for people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer. 70 patients in China took part. The goal was to see if the transplant c…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New oral combo shows promise for rare blood cancer
Disease control CompletedThis study tested a treatment plan using thalidomide, cyclophosphamide, and dexamethasone, followed by long-term thalidomide and prednisone, in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the oral regimen control…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare blood cancer: which drug combo works best?
Disease control CompletedThis study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination better controls the disease and improves survival without progression. Participants received either rituxi…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo shows promise for rare blood cancer, may limit lifelong treatment
Disease control CompletedThis study tested a combination of three drugs (zanubrutinib, ixazomib, and dexamethasone) in 25 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to 24 months and then stopped, aiming to achieve deep remission and redu…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New PET tracer aims to spot hidden cancers without biopsy
Diagnosis CompletedThis completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC